Alzex Neuropharma Inc. (TRRI)
| Market Cap | 301.00 |
| Revenue (ttm) | 4.73M |
| Net Income (ttm) | 32.05K |
| Shares Out | 1.51M |
| EPS (ttm) | n/a |
| PE Ratio | 0.01 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 6,500 |
| Average Volume | 2,160 |
| Open | 0.0003 |
| Previous Close | 0.0003 |
| Day's Range | 0.0002 - 0.0003 |
| 52-Week Range | 0.0002 - 0.1980 |
| Beta | -53.95 |
| RSI | 42.25 |
| Earnings Date | n/a |
About Alzex Neuropharma
Alzex Neuropharma Inc., a development stage biopharmaceutical company, engages in developing therapeutics for the treatment of Alzheimer's Disease and other neurological diseases. The company was formerly known as Trinity Resources Inc. and changed its name to Alzex Neuropharma Inc. in December 2022. The company was incorporated in 1971 and is headquartered in Las Vegas, Nevada. [Read more]
Financial Performance
In 2011, Alzex Neuropharma's revenue was $4.73 million, an increase of 23.83% compared to the previous year's $3.82 million. Earnings were $32,053, a decrease of -59.83%.
Financial StatementsNews
Trinity Resources Inc. Awaiting Regulatory Approval of Name and Symbol Change
Las Vegas, Nevada--(Newsfile Corp. - December 16, 2022) - TRINITY RESOURCES INC. (OTC Pink: TRRI) (the "Company" or "Trinity") announces that further to its news release on August 29, 2022, it has app...
Trinity Resources Inc. Finalizes the Purchase of Alzex Biomedical Assets and Intellectual Property
-Planning a New Approach to Treat Alzheimer's Disease-Las Vegas, Nevada--(Newsfile Corp. - August 4, 2022) - TRINITY RESOURCES INC. (OTC Pink: TRRI) (the "Company" or "Trinity") is pleased to announce...